Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development

Current Pharmaceutical Design

Volumn 19, Issue 3, 2013, Pages 366-376

  Soga, Shiro ^a   Akinaga, Shiro ^a   Shiotsu, Yukimasa ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Cancer; Hsp90; Molecular target therapeutics

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; AT 113387; AT 13387; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; IMATINIB; KF 25706; KF 58333; KW 2478; RADICICOL; RESORCINOL DERIVATIVE; RETASPIMYCIN; SNX 5422; TANESPIMYCIN; UNCLASSIFIED DRUG;

BLURRED VISION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG SAFETY; FATIGUE; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; INFANTILE DIARRHEA; LIVER TOXICITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; THROMBOCYTE;

EID: 84876717451     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804143617     Document Type: Review

References (66)

1. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28.
2. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
3. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-49.
4. Kim YS, Alarcon SV, Lee S, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009; 9: 1479-92.
5. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012; 18: 64-76
6. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012, 1823: 742-55.
7. Uehara Y. Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets 2003; 3: 325-30.
8. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8.
9. Soga S, Kozawa T, Narumi H, et al. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway. J Biol Chem 1998; 273: 822-8.
10. Schulte TW, Akinaga S, Soga S, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998; 3: 100-8.
11. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998; 16: 2639-45
12. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42: 260-6.
13. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005; 11: 1131-8.
14. Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Top Med Chem 2009; 9: 1386-418.
15. Soga S, Shiotsu Y, Akinaga S, Sharma SV. Development of radicicol analogues. Curr Cancer Drug Targets 2003; 3: 359-69.
16. Ikuina Y, Amishiro N, Miyata M, et al. Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol. J Med Chem 2003; 46: 2534-41
17. Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999; 59: 2931-8
18. Zheng FF, Kuduk SD, Chiosis G, et al. Identification of a geldanamycin dimer that induces the selective degradation of HERfamily tyrosine kinases. Cancer Res 2000; 60: 2090-4.
19. Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H. A radicicol derivative, KF58333, inhibits expression of hypoxiainducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 2001; 92: 1342-51.
20. Soga S, Sharma SV, Shiotsu Y, et al. Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother Pharmacol 2001; 48: 435-45
21. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2011; 102: 1-8.
22. Chandarlapaty S, Scaltriti M, Angelini P, et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010; 29: 325-34.
23. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
24. Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 1989; 49: 331-4.
25. Okabe M, Uehara Y, Miyagishima T, et al. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 1992; 80: 1330-8.
26. Honma Y, Kasukabe T, Hozumi M, et al. Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity. Leukemia 1992; 6: 229-31
27. Shiotsu Y, Neckers LM, Wortman I, et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000; 96: 2284-91.
28. Shiotsu Y, Soga S, Akinaga S. Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex. Leuk Lymphoma 2002; 43: 961-8.
29. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosminanaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002; 62: 1559-66.
30. Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011; 30: 2581-6.
31. Nakashima T, Ishii T, Tagaya H, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010; 16: 2792-802.
32. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092-100.
33. Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011; 152: 367-79.
34. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-73.
35. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-98.
36. Agnelli L, Bicciato S, Mattioli M, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005; 23: 7296-306.
37. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97: 228-33.
38. Lombardi L, Poretti G, Mattioli M, et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46: 226-38.
39. Yong K, Cavet J, Johnson P, et al. A first-in-man, Phase I, multicenter, open-label, dose escalation study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. 13th International Myeloma Workshop, May 3-6, 2011, Paris, P-145.
40. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 5410-7.
41. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17: 5132-9.
42. Richardson PG, Chanan-Khan AA, Lonial S, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol 2011; 153: 729-40.
43. Bristol-Myers Squibb Halts Development of Tanespimycin [homepage on the internet], The Myeloma Beacon [published: Jul 22, 2010; cited Jan 8, 2012]. Available from; http: //www.myelomabeacon. com/news/2010/07/22/tanespimycin-development-halted/
44. Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies. Available from: http: //clinicaltrials. gov/ct2/show/NCT00820768?term=ABI-010&rank=1 [Updated July 14, 2011]
45. Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors. Infinity Pharmaceutical Inc Press Release: http: //phx. corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle& ID=1595891&highlight=IPI-504 [Updated April 15, 2009]
46. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010; 28: 4953-60.
47. Infinity Initiates Randomized Phase 2 Trial of IPI-504, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer. Infinity Pharmaceutical Inc Press Release: http: //phx.corporate-ir.net/phoenix. zhtml?c=121941&p=irol-newsArticle&ID=1595416&highlight= IPI-493 [Updated May 19, 2011]
48. Ide S, Motwani M, Jensen MR, et al. Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. J Clin Oncol 2009; 27: 15s, 2009 (suppl; abstr 3533).
49. Samuel TA, Sessa C, Britten C, et al. AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol 2010; 28: 15s (suppl; abstr 2528)
50. Schroder CP, Pedersen JV, Chua S, et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. J Clin Oncol 2011; 9: (suppl; abstr e11024)
51. Onozawa Y, Doi T, Yamazaki K, et al. AUY922, a novel HSP90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies. AACR-NCIEORTC 2011, Presentation Abstract B98
52. Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients. http: //clinicaltrials.gov/ct2/show/NCT01402401?term=AUY-922&rank=11 [Updated Dec 13, 2011; cited Jan 8, 2012]
53. A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. Available from: http: //clinicaltrials.gov/ct2/show/ NCT00708292?term=AUY-922&rank=1 [Updated Aug 10, 2011; cited Jan 8, 2012]
54. Menezes D, Taverna P, Jensen MR, et al. The novel oral HSP90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol Cancer Ther 2012; 11: 730-9.
55. Woodhead AJ, Angove H, Carr MG, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010; 53: 5956-69.
56. A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST. Available from: http: //clinicaltrials.gov/ct2/show/NCT01294202?term= AT13387&rank=1 [Updated Nov 8, 2011; cited Jan 8, 2012]
57. Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a smallmolecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 2010; 11: 1466-76.
58. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolonecontaining Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11: 475-84
59. Mitchell P. Biogen Idec restructures, sharpens neurology focus. Nat Biotechnol 2011; 29: 7-8.
60. Chiosis G, Timaul MN, Lucas B, et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001; 8: 289-99.
61. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PUH71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009; 106: 8368-73.
62. Fadden P, Huang KH, Veal JM, et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 2010; 17: 686-694.
63. Rajan A, Kelly RJ, Trepel JB, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011; 17: 6831-9.
64. Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110: 678-85.
65. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108: 7535-40.
66. Lindquist S. Protein folding sculpting evolutionary change. Cold Spring Harb Symp Quant Biol 2009; 74: 103-8.